Our Seedrs crowdfunding campaign has now closed with an amazing £2.85 million from over 850 investors!
Thank you for joining us on our journey to bring highly disruptive non-contacting screening, monitoring and ophthalmic products to market.
When investing your capital is at risk. Approved by Seedrs
What is Crowdfunding?
Crowdfunding is the term generally used to describe a person or company raising funds from a large number of people (the crowd). Crowdfunding has been fuelled by the growth of the internet, allowing people who previously could only reach small networks and sums of money to now reach much wider audiences and in turn raise more money.
What is Equity Crowdfunding?
Seedrs is an equity crowdfunding platform. This means that you will own equity (shares) in Occuity in return for your investment.
What are the Benefits of Equity Crowdfunding?
Equity crowdfunding allows you to buy into a business you believe in, and to therefore have a financial share of the rewards of any potential success of that business.
When investing in early-stage businesses, you should be aware that your capital is at risk.
If the business performs well, the value of your shares may rise. If you decide to sell your shares one day, you will profit from the increase in value on those shares.
Say, for example, a company called StarTech, is raising money via equity crowdfunding, and you wish to invest. StarTech prices its shares at £10 per share, and you invest £100. This means you buy 10 StarTech shares (£100/£10 = 10). Your investment was a savvy one and StarTech grows fast over the next 5 years, such that the company’s value increases tenfold. The 10 shares you bought for £100 are now worth £1000.
As with all investing, equity crowdfunding comes with risks that investors should be aware of, such as loss of capital, illiquidity, and dilution.
Read more about Seedrs & Equity Crowdfunding here
Why is Occuity Crowdfunding?
Occuity has an ambitious mission - to improve the lives of millions of people who currently have to endure regular, painful and invasive testing for conditions such as diabetes.
We're researching and developing a pain-free non-invasive solution, but this takes time and money due to the strict processes that must be followed to deliver a medical device.
Our Seedrs crowdfunding campaign has two great benefits.
It gives you the opportunity to help us accelerate the development of our technology by investing in things such as growing our team and running clinical trials of our products such as our non-invasive optical glucose monitor.
It's a great opportunity for you to join us on our journey by becoming a shareholder and being part of our future.
We know that our solution is needed, and comments from our diabetes community have backed this up.
If you would like to see our unique products come to market, you can support our work by becoming a shareholder and joining us on our mission to deliver social & commercial value.
Register today to be the first to hear about the launch of our campaign. There is no commitment to invest.
'Capital at Risk'
We're aiming to revolutionise the way in which some of the world’s most prevalent chronic diseases are detected and managed. Our devices work by harmlessly shining a low power beam of light into the eye, collecting and analysing the return signal.
We are developing a novel, globally patented (9 granted, 5 pending, 1 in process) non-contacting technology that will aim to accurately detect changes in the eye and thereby derive information not only about a patient’s ocular health but also about their broader wellbeing, particularly where this relates to chronic, life-changing conditions.
Occuity is developing its disruptive technology into a range of handheld devices aimed at some of the major health problems of our time. Due to the size of the market, we are particularly interested in addressing diabetes by both developing products that will enable earlier diagnosis of the condition and will also enable non-contacting, pain-free glucose monitoring.
Our first product using the patented technology will be the Occuity PM1 pachymeter, a handheld device for opticians to optically measure the thickness of the cornea to support glaucoma diagnosis. The prototype will soon be submitted for clinical trials and is planned to be ready for sale in H2 2022. Therefore, we believe it is therefore set to disrupt a market worth an estimated $1Bn pa.
Following on from this will be more advanced meters to screen first for diabetes, then for Alzheimer’s Disease and then a personal blood glucose meter for use by people with diabetes. Our products will address markets that we estimate to be collectively worth around $35Bn pa.
Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. This page has been approved as a financial promotion by Seedrs Limited, which is authorised and regulated by the Financial Conduct Authority (No. 550317).